Amanda L. Gross

ORCID: 0000-0003-2285-9847
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lysosomal Storage Disorders Research
  • Glycosylation and Glycoproteins Research
  • Neuroscience and Neuropharmacology Research
  • Virus-based gene therapy research
  • Stress Responses and Cortisol
  • Epilepsy research and treatment
  • Monoclonal and Polyclonal Antibodies Research
  • Treatment of Major Depression
  • Adenosine and Purinergic Signaling
  • Memory and Neural Mechanisms
  • Pharmacological Effects and Toxicity Studies
  • Advanced Biosensing Techniques and Applications
  • RNA regulation and disease
  • Neurogenetic and Muscular Disorders Research
  • Neuropeptides and Animal Physiology
  • Cellular transport and secretion
  • Growth Hormone and Insulin-like Growth Factors
  • Erythrocyte Function and Pathophysiology
  • Bacteriophages and microbial interactions
  • Psychiatric care and mental health services
  • Tryptophan and brain disorders
  • Galectins and Cancer Biology
  • Child and Animal Learning Development
  • Rabies epidemiology and control
  • Viral Infections and Outbreaks Research

Auburn University
2015-2024

Aptinyx (United States)
2017-2019

Afraxis (United States)
2017

Northwestern University
2012-2017

New York Medical College
2015-2017

The University of Texas at San Antonio
2007

Overweight and obesity are growing health problems in domestic cats, increasing the risks of insulin resistance, lipid dyscrasias, neoplasia, cardiovascular disease, decreasing longevity. The signature feline gut microbiota has not been studied at whole-genome metagenomic level. We performed shotgun sequencing fecal samples eight overweight/obese normal cats housed same research environment. obtained 271 Gbp sequences generated a 961-Mbp de novo reference contig assembly, with 1.14 million...

10.1128/spectrum.00837-22 article EN cc-by Microbiology Spectrum 2022-04-25

N-methyl-D-aspartate receptors are one member of a family ionotropic glutamate that play pivotal role in synaptic plasticity processes associated with learning and have become attractive therapeutic targets for diseases such as depression, anxiety, schizophrenia, neuropathic pain. NYX-2925 ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide) is spiro-β-lactam-based chemical platform mimics some the dipyrrolidine structural features rapastinel (formerly...

10.1093/ijnp/pyx096 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2017-10-17

Polymersomes are created to deliver an enzyme-based therapy the brain in lysosomal storage disease patients.Polymersomes formed via injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound apolipoprotein E, create a brain-targeted delivery vehicle.Polymersomes have smallest average diameter of 145 ± 21 nm encapsulate β-galactosidase at 72.0 12.2% efficiency. PEGPLA polymersomes demonstrate limited release physiologic pH (7.4), with burst acidic (4.8) lysosome....

10.2217/nnm-2017-0221 article EN Nanomedicine 2017-11-07

Modulation of glutamatergic synaptic transmission by N-methyl-D-aspartate receptors can produce rapid and sustained antidepressant effects. Rapastinel (GLYX-13), initially described as a receptor partial glycine site agonist, exhibits effect in rodents without the accompanying dissociative effects antagonists.The relationship between rapastinel's vitro pharmacology efficacy was determined brain microdialysis subsequent pharmacological characterization therapeutic rapastinel concentrations...

10.1093/ijnp/pyy101 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2018-01-13

Growth factors play an important role in regulating neurogenesis and synapse formation may be involved the antidepressant response to conventional antidepressants. To date, Insulin-like growth factor I (IGFI) is only that has shown properties human clinical trials. However, its mechanism of action remains unclear. The antidepressant-like effect a single IV dose IGFI was determined using chronic unpredictable stress paradigm rat Porsolt, sucrose preference, novelty-induced hypophagia,...

10.1093/ijnp/pyv101 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2015-09-15

GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by mutations in the GLB1 gene, which encodes lysosomal hydrolase acid β-galactosidase (β-gal). β-gal deficiency leads to toxic accumulation of ganglioside, predominantly central nervous system (CNS), resulting progressive neurodegeneration. LYS-GM101 an AAVrh.10-based gene therapy vector carrying human cDNA. The efficacy intra-cerebrospinal fluid injection analogs was demonstrated mouse and cat models with widespread...

10.1016/j.omtm.2022.10.004 article EN cc-by-nc-nd Molecular Therapy — Methods & Clinical Development 2022-10-07

GM1 gangliosidosis (GM1) is a fatal neurodegenerative lysosomal storage disease that occurs most commonly in young children, with no effective treatment available. Long-term follow-up of cats treated by bilateral thalamic and deep cerebellar nuclei (DCN) injection adeno-associated virus (AAV)-mediated gene therapy has increased lifespan to 8 years age, compared an untreated ~8 months. Due risks associated humans, the lateral ventricle was tested as replacement route deliver AAVrh8 vector...

10.1016/j.omtm.2019.11.023 article EN cc-by-nc-nd Molecular Therapy — Methods & Clinical Development 2019-12-24

Posttraumatic stress disorder is an anxiety characterized by deficits in the extinction of aversive memories. Insulin-like growth factor 1 (IGF1) only that has shown anxiolytic and antidepressant properties human clinical trials. In animal studies, insulin-like binding protein 2 (IGFBP2) shows both IGF1-dependent IGF1-independent pharmacological effects, IGFBP2 expression upregulated rough-and-tumble play induces resilience to stress.IGFBP2 was evaluated Porsolt, contextual fear...

10.1093/ijnp/pyx007 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2017-01-30

Models of hippocampal function suggest that the modulation CA3 afferent input during theta rhythm allows for a rapid alternation between encoding and retrieval states, with each phase enhancing either extrinsic or intrinsic afferents, favoring retrieval, respectively. Here, we show initial exploration novel environment by rats, CA3-CA3 synaptic inputs are attenuated on peaks, inputs, whereas perforant path-CA3 troughs, inputs. This is absent when animals re-exposed to same 2 48 h later thus...

10.1523/jneurosci.3702-07.2007 article EN cc-by-nc-sa Journal of Neuroscience 2007-12-05

Active tumor targeting of nanomedicines has recently shown significant improvements in the therapeutic activity currently existing drug delivery systems, such as liposomal doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have that isolated pVIII major coat proteins fd tet filamentous phage vector, containing cancer cell-specific peptide fusions at their N terminus, can be used active ligands a system vitro and vivo. Here, show novel protein isolation procedure 2-propanol allows spontaneous...

10.3389/fmicb.2015.00628 article EN cc-by Frontiers in Microbiology 2015-06-23

Abstract GM1 gangliosidosis is a fatal neurodegenerative disease caused by deficiency of lysosomal β-galactosidase. In its most severe form, causes death 4 years age, and no effective treatments exist. Previous work has shown that injection the brain parenchyma with an adeno-associated viral (AAV) vector provides pronounced therapeutic benefit in feline model. To develop less invasive treatment for increase systemic biodistribution, intravenous AAV9 was evaluated. expressing β-galactosidase...

10.1093/brain/awab309 article EN Brain 2021-08-17

Cancer cell-specific targeting ligands against numerous cancer cell lines have been selected previously and used as for delivery of chemotherapies various nanomedicines. However, tumor heterogeneity is one recognized problem hampering clinical translation targeted anti-cancer medicines. Therefore, a novel class required that recognize receptors expressed between variety phenotypes, identified here 'promiscuous' ligands. In this work, promiscuous phage fusion proteins were first by selection...

10.1093/protein/gzv064 article EN Protein Engineering Design and Selection 2016-01-12

GM2 gangliosidosis is usually fatal by 5 years of age in its 2 major subtypes, Tay-Sachs and Sandhoff disease. First reported 1881, has no effective treatment today, children succumb to the disease after a protracted neurodegenerative course semi-vegetative state. This study seeks further develop adeno-associated virus (AAV) gene therapy for human translation.

10.1002/ana.26756 article EN Annals of Neurology 2023-08-01

Abstract Rabies is the deadliest viral infection known, with no reliable treatment, and although it entirely preventable, rabies continues to kill more than 60,000 people every year, mostly children in countries where dog endemic. America only 1 generation away from time when killed 10,000 animals 50 Americans but 3 5 continue die annually rabies. Distressingly, > 50,000 undergo prevention therapy year after exposure potentially rabid animals. While enormous progress has been made, must...

10.2460/javma.22.09.0420 article EN Journal of the American Veterinary Medical Association 2022-12-07

Introduction Phenobarbital has been used for many decades in both human and veterinary epileptic patients. Many formulations a particular drug exist, most of which are marketed humans. Recently specific phenobarbital product introduced to the market United States. Utilizing formulation treat patients may help decrease issue bioequivalence between one pharmaceutical another. Therefore, goal this study was determine single multiple dosing pharmacokinetics tolerability over 4-week time period....

10.3389/fvets.2023.1307888 article EN cc-by Frontiers in Veterinary Science 2024-01-05

The number of available antiseizure medications with demonstrated efficacy in cats is limited. As such, there a need to evaluate the pharmacokinetics newer so that proper dosing regimens can be made. Brivaracetam (BRV) more potent analogue levetiracetam, and Food Drug Administration approved for use people. goal this study was describe intravenous oral doses BRV healthy cats. A cross-over involving eight cats, were administered 10 mg intravenously as bolus orally fasted state. Blood samples...

10.1111/jvp.13473 article EN Journal of Veterinary Pharmacology and Therapeutics 2024-07-17
Coming Soon ...